Eur J Pharmacol 553, 141-145, (2006). Brammer, M. K., Gilmore, D. L., & Matsumoto, R. R. View abstract in PubMed Post navigationPreviousPrevious post:Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia.NextNext post:Sigma receptor type 1 gene expression variation in a group of Polish patients with Alzheimer’s disease and mild cognitive impairment.Related PostsAnavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease DementiaOctober 15, 2020Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical TrialSeptember 10, 2020Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Parkinson’s DiseaseAugust 19, 2020Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)July 6, 2020
Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease DementiaOctober 15, 2020
Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical TrialSeptember 10, 2020
Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Parkinson’s DiseaseAugust 19, 2020
Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)July 6, 2020
